Agios Pharmaceuticals Inc (AGIO)
32.19
-0.59
(-1.80%)
USD |
NASDAQ |
May 08, 15:25
Agios Pharmaceuticals Free Cash Flow (Quarterly): -100.01M for March 31, 2024
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | -100.01M |
December 31, 2023 | -72.72M |
September 30, 2023 | -79.51M |
June 30, 2023 | -66.74M |
March 31, 2023 | -95.58M |
December 31, 2022 | -66.28M |
September 30, 2022 | -71.39M |
June 30, 2022 | -76.16M |
March 31, 2022 | -100.54M |
December 31, 2021 | -88.60M |
September 30, 2021 | -85.16M |
June 30, 2021 | -117.54M |
March 31, 2021 | -121.76M |
December 31, 2020 | -49.96M |
September 30, 2020 | -73.41M |
June 30, 2020 | -71.94M |
March 31, 2020 | -109.55M |
December 31, 2019 | -100.29M |
September 30, 2019 | -87.63M |
June 30, 2019 | -89.42M |
March 31, 2019 | -105.31M |
December 31, 2018 | -75.24M |
September 30, 2018 | -66.98M |
June 30, 2018 | -68.76M |
March 31, 2018 | -100.43M |
Date | Value |
---|---|
December 31, 2017 | -75.73M |
September 30, 2017 | -79.73M |
June 30, 2017 | -60.02M |
March 31, 2017 | -74.37M |
December 31, 2016 | -52.44M |
September 30, 2016 | -52.46M |
June 30, 2016 | 155.09M |
March 31, 2016 | -21.54M |
December 31, 2015 | -32.72M |
September 30, 2015 | -28.11M |
June 30, 2015 | -6.902M |
March 31, 2015 | -29.38M |
December 31, 2014 | -9.264M |
September 30, 2014 | -24.10M |
June 30, 2014 | -1.157M |
March 31, 2014 | -27.05M |
December 31, 2013 | -13.84M |
September 30, 2013 | -15.08M |
June 30, 2013 | -16.52M |
March 31, 2013 | -12.26M |
December 31, 2012 | -11.66M |
September 30, 2012 | -12.54M |
June 30, 2012 | -10.83M |
March 31, 2012 | -16.00M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-121.76M
Minimum
Mar 2021
-49.96M
Maximum
Dec 2020
-86.21M
Average
-86.39M
Median
Free Cash Flow (Quarterly) Benchmarks
Alnylam Pharmaceuticals Inc | -94.49M |
Amgen Inc | 459.00M |
Blueprint Medicines Corp | -102.62M |
Corcept Therapeutics Inc | 23.76M |
Ionis Pharmaceuticals Inc | 32.89M |